vs
WAFD INC（WAFD）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
WAFD INC的季度营收约是再鼎医药的1.5倍（$191.4M vs $127.1M），再鼎医药同比增速更快（17.1% vs 11.8%），WAFD INC自由现金流更多（$50.0M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 5.5%）
WAFD银行总部位于美国华盛顿州西雅图市，是美国头部银行之一，业务覆盖华盛顿州、俄勒冈州、爱达荷州、内华达州、犹他州、亚利桑那州、新墨西哥州、加利福尼亚州及得克萨斯州，共设有210家实体营业网点，为多州客户提供专业金融服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
WAFD vs ZLAB — 直观对比
营收规模更大
WAFD
是对方的1.5倍
$127.1M
营收增速更快
ZLAB
高出5.3%
11.8%
自由现金流更多
WAFD
多$76.7M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
5.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $191.4M | $127.1M |
| 净利润 | $64.2M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 43.0% | -54.6% |
| 净利率 | 33.5% | — |
| 营收同比 | 11.8% | 17.1% |
| 净利润同比 | 35.8% | — |
| 每股收益（稀释后） | $0.79 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收WAFDZLAB
| Q4 25 | $191.4M | $127.1M | ||
| Q3 25 | $188.3M | $115.4M | ||
| Q2 25 | $186.3M | $109.1M | ||
| Q1 25 | $179.8M | $105.7M | ||
| Q4 24 | $171.1M | $108.5M | ||
| Q3 24 | $188.7M | $101.8M | ||
| Q2 24 | $194.4M | $100.1M | ||
| Q1 24 | $172.0M | $87.1M |
净利润WAFDZLAB
| Q4 25 | $64.2M | — | ||
| Q3 25 | $60.6M | $-36.0M | ||
| Q2 25 | $62.0M | $-40.7M | ||
| Q1 25 | $56.3M | $-48.4M | ||
| Q4 24 | $47.3M | — | ||
| Q3 24 | $61.1M | $-41.7M | ||
| Q2 24 | $64.6M | $-80.3M | ||
| Q1 24 | $15.9M | $-53.5M |
毛利率WAFDZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率WAFDZLAB
| Q4 25 | 43.0% | -54.6% | ||
| Q3 25 | 41.2% | -42.3% | ||
| Q2 25 | 42.8% | -50.3% | ||
| Q1 25 | 40.1% | -53.3% | ||
| Q4 24 | 35.2% | -62.6% | ||
| Q3 24 | 42.8% | -66.6% | ||
| Q2 24 | 42.6% | -76.0% | ||
| Q1 24 | 12.2% | -80.7% |
净利率WAFDZLAB
| Q4 25 | 33.5% | — | ||
| Q3 25 | 32.2% | -31.2% | ||
| Q2 25 | 33.3% | -37.3% | ||
| Q1 25 | 31.3% | -45.8% | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 32.4% | -40.9% | ||
| Q2 24 | 33.2% | -80.2% | ||
| Q1 24 | 9.2% | -61.4% |
每股收益（稀释后）WAFDZLAB
| Q4 25 | $0.79 | $-0.05 | ||
| Q3 25 | $0.71 | $-0.03 | ||
| Q2 25 | $0.73 | $-0.04 | ||
| Q1 25 | $0.65 | $-0.04 | ||
| Q4 24 | $0.54 | $-0.09 | ||
| Q3 24 | $0.73 | $-0.04 | ||
| Q2 24 | $0.75 | $-0.08 | ||
| Q1 24 | $0.17 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $734.9M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.0B | $715.5M |
| 总资产 | $27.3B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资WAFDZLAB
| Q4 25 | $734.9M | $689.6M | ||
| Q3 25 | $657.3M | $717.2M | ||
| Q2 25 | $809.3M | $732.2M | ||
| Q1 25 | $1.2B | $757.3M | ||
| Q4 24 | $1.5B | $779.7M | ||
| Q3 24 | $2.4B | $616.1M | ||
| Q2 24 | $2.5B | $630.0M | ||
| Q1 24 | $1.5B | $650.8M |
股东权益WAFDZLAB
| Q4 25 | $3.0B | $715.5M | ||
| Q3 25 | $3.0B | $759.9M | ||
| Q2 25 | $3.0B | $791.7M | ||
| Q1 25 | $3.0B | $810.8M | ||
| Q4 24 | $3.0B | $840.9M | ||
| Q3 24 | $3.0B | $667.7M | ||
| Q2 24 | $3.0B | $704.2M | ||
| Q1 24 | $2.9B | $762.2M |
总资产WAFDZLAB
| Q4 25 | $27.3B | $1.2B | ||
| Q3 25 | $26.7B | $1.2B | ||
| Q2 25 | $26.7B | $1.2B | ||
| Q1 25 | $27.6B | $1.2B | ||
| Q4 24 | $27.7B | $1.2B | ||
| Q3 24 | $28.1B | $985.3M | ||
| Q2 24 | $28.6B | $987.4M | ||
| Q1 24 | $30.1B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.5M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $50.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 26.1% | -21.0% |
| 资本支出强度资本支出/营收 | 5.5% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.94× | — |
| 过去12个月自由现金流最近4个季度 | $377.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流WAFDZLAB
| Q4 25 | $60.5M | $-26.0M | ||
| Q3 25 | $237.0M | $-32.0M | ||
| Q2 25 | $58.0M | $-31.0M | ||
| Q1 25 | $72.1M | $-61.7M | ||
| Q4 24 | $49.4M | $-55.8M | ||
| Q3 24 | $439.2M | $-26.8M | ||
| Q2 24 | $63.1M | $-42.2M | ||
| Q1 24 | $169.2M | $-90.1M |
自由现金流WAFDZLAB
| Q4 25 | $50.0M | $-26.7M | ||
| Q3 25 | $208.2M | $-35.0M | ||
| Q2 25 | $53.1M | $-33.9M | ||
| Q1 25 | $66.6M | $-63.2M | ||
| Q4 24 | $43.0M | $-58.4M | ||
| Q3 24 | $414.6M | $-28.2M | ||
| Q2 24 | $58.3M | $-42.9M | ||
| Q1 24 | $164.8M | $-91.1M |
自由现金流率WAFDZLAB
| Q4 25 | 26.1% | -21.0% | ||
| Q3 25 | 110.6% | -30.4% | ||
| Q2 25 | 28.5% | -31.1% | ||
| Q1 25 | 37.0% | -59.9% | ||
| Q4 24 | 25.1% | -53.8% | ||
| Q3 24 | 219.7% | -27.7% | ||
| Q2 24 | 30.0% | -42.9% | ||
| Q1 24 | 95.8% | -104.5% |
资本支出强度WAFDZLAB
| Q4 25 | 5.5% | 0.5% | ||
| Q3 25 | 15.2% | 2.6% | ||
| Q2 25 | 2.6% | 2.6% | ||
| Q1 25 | 3.1% | 1.5% | ||
| Q4 24 | 3.8% | 2.4% | ||
| Q3 24 | 13.1% | 1.3% | ||
| Q2 24 | 2.5% | 0.7% | ||
| Q1 24 | 2.6% | 1.1% |
现金转化率WAFDZLAB
| Q4 25 | 0.94× | — | ||
| Q3 25 | 3.91× | — | ||
| Q2 25 | 0.94× | — | ||
| Q1 25 | 1.28× | — | ||
| Q4 24 | 1.05× | — | ||
| Q3 24 | 7.18× | — | ||
| Q2 24 | 0.98× | — | ||
| Q1 24 | 10.65× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
WAFD
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
